A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma
-
By
-
Zhang, Huaichao
-
Yang, Zijiang
-
Xie, Qiang
-
Chen, Pin
-
Huang, Jinlong
-
Liu, Shuang
-
Li, Zeyang
-
Sun, Wei
-
Zhang, Xiaobiao
-
Xie, Tao
-
May 4, 2026
-
Clinical Scorecard: A Tumor Signature Based on Cell Death Programs Predicts Prognosis, Immune Environment, and Treatment Response in Glioma
At a Glance
| Category | Detail |
|---|
| Condition | Glioma |
| Key Mechanisms | Pyroptosis-apoptosis-associated gene signature (PA.Sig) linked to inflammatory cell death and tumor microenvironment interactions. |
| Target Population | Patients with glioma |
| Care Setting | Oncology |
Key Highlights
- PA.Sig stratifies glioma patients into high- and low-risk groups based on overall survival.
- High-risk tumors show increased somatic mutation burden and immune dysfunction.
- Single-cell analyses reveal enriched MES-like states in high-risk tumors.
- Chemotherapy induces both apoptotic and pyroptotic cell death in glioma cells.
- PA.Sig serves as a prognostic biomarker for glioma treatment strategies.
Guideline-Based Recommendations
Diagnosis
- Utilize PA.Sig for prognostic assessment in glioma patients.
Management
- Consider combinatorial strategies targeting cell death pathways and immune modulation.
Monitoring & Follow-up
- Monitor genomic alterations and immune microenvironment dynamics in glioma.
Risks
- High-risk tumors may exhibit immune exhaustion despite increased immune infiltration.
Patient & Prescribing Data
Patients diagnosed with glioma exhibiting high-risk features.
Incorporate PA.Sig in treatment planning to enhance therapeutic responses.
Clinical Best Practices
- Integrate transcriptomic data for personalized treatment approaches.
- Evaluate tumor microenvironment interactions during therapy.
Related Resources & Content
